Form 4: Relay Therapeutics Director Sekar Kathiresan Acquires Stock Options

Director Sekar Kathiresan of Relay Therapeutics, Inc. reports the acquisition of stock options on June 3, 2024.

Summary

• Sekar Kathiresan, a director of Relay Therapeutics, Inc., filed a Form 4 on June 5, 2024, reporting a transaction.
• On June 3, 2024, Kathiresan acquired stock options for 102,225 shares of Relay Therapeutics common stock at an exercise price of $6.79.
• These options vest fully on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders following the grant date.
• Following the reported transaction, Kathiresan directly owns options for 102,225 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. There's no indication of significant positive or negative news.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates